Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT00672412 Completed - HIV Infections Clinical Trials

Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

Start date: October 2008
Phase: Phase 1/Phase 2
Study type: Interventional

In 2005, there were 50,620 HIV-infected children living in Thailand. Current anti-HIV regimens, comprised of individual pills for each drug, frequently lead to missed doses. To properly control their infection, regimens that are tolerable and effective in children and without pill burden are necessary. The primary purpose of this study is to evaluate the safety and bioavailability of GPO-VIR Z30, a combination fixed dose tablet containing zidovudine (ZDV), lamivudine (3TC), and nevirapine (NVP), in HIV-infected children in Thailand.

NCT ID: NCT00672191 Completed - HIV Infections Clinical Trials

Phase II Study of AGS‑004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.

NCT ID: NCT00670839 Completed - HIV Infection Clinical Trials

Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)

B-BOOST
Start date: May 2008
Phase: Phase 3
Study type: Interventional

HIV infected patients exposed to Hepatitis B virus are more susceptible to develop a chronic and severe liver disease, with a major risk of cirrhosis and liver cancer. However, immune response to standard Hepatitis B vaccination is decreased in HIV-infected patients, compared to non HIV-infected individuals, and, in case of response, its durability has to be carefully followed up. This study compares the efficacy of two strategies of revaccination in HIV-infected patients who didn't respond to previous hepatitis B vaccination. Failure is defined by two conditions: non response to the primary immunization (2 to 4 single-dose injections received before the screening visit) and failure to a single 20 µg boost before being included in the study.

NCT ID: NCT00670163 Completed - HIV Infections Clinical Trials

Effectiveness of Community-Level Behavioral and Biomedical Interventions for Reducing HIV/STIs in Men in Peru

Start date: April 2008
Phase: N/A
Study type: Interventional

This study will evaluate the effectiveness of community-level behavioral and biomedical interventions, each alone and combined, in reducing sexual risk behavior and HIV/sexually transmitted infections in Peruvian men who have sex with men.

NCT ID: NCT00669604 Completed - HIV Infections Clinical Trials

HIV Vertical Transmission in Vietnam

Start date: March 2004
Phase: N/A
Study type: Observational

Prevention of HIV-1 transmission from mother-to-child by non-breast-feeding is complicated by increased infant mortality in developing countries. However, extensive counselling about formula feeding turned out safe in Vietnam, a middle-income country.Extensive counselling together with formula feeding and antiretroviral therapy reduced vertical transmission of HIV-1 considerably.

NCT ID: NCT00669487 Completed - HIV Infections Clinical Trials

A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP

Start date: April 2008
Phase: Phase 3
Study type: Interventional

This protocol aims to determine the risk/benefits of this policy by comparing head-to-head a regimen of GPO-VIR Z or TDF/FTC/NVP for 18 months in ARV-naïve patients to a 6-month lead in with GPO-VIR S followed by 12 months of GPO-VIR Z. The primary outcomes to be assessed will be anemia, neuropathy, lipoatrophy and renal function.

NCT ID: NCT00668356 Suspended - HIV Infections Clinical Trials

Bioequivalence Study of Didanosine in Children Treated for HIV

ddI
Start date: September 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to show that the administration of 400/mg/m2/day of didanosine(ddI) during the meal is bioequivalent to the administration of 240/mg/m2/day of didanosine during fasting, in HIV infected children treated by a ARV combination including ddI

NCT ID: NCT00667433 Completed - HIV Infections Clinical Trials

Raltegravir as Early Therapy in African-Americans Living With HIV Study

REAL
Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is a single arm, longitudinal study to examine the safety, tolerability, and pharmacokinetic and metabolic characteristics of Raltegravir among 40 African-American, HIV-infected, patients.

NCT ID: NCT00667186 Completed - HIV Infections Clinical Trials

HIV Screening in the Emergency Department Setting

Start date: January 2008
Phase: N/A
Study type: Interventional

Late diagnosis of HIV infection is believed to be responsible for high rates of HIV transmission. The purpose of this study is to determine whether targeted screening versus routine screening will identify a greater number of HIV infected participants. This study will also compare the costs of the resources used for targeted screening versus routine screening.

NCT ID: NCT00666107 Active, not recruiting - HIV Infections Clinical Trials

Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men

MIRB #862
Start date: June 2008
Phase: N/A
Study type: Interventional

This study will investigate the efficacy and safety of the quadrivalent vaccine (Gardasil) against the human papilloma virus (HPV) in HIV (human immunodeficiency virus) infected males.